BMS wins FDA OK for Sustiva in babies, toddlers
This article was originally published in Scrip
Executive Summary
The US FDA has granted Bristol-Myers Squibb permission to markets its HIV drug Sustiva (efavirenz) for use in pediatric patients three months to three-years-old and weighing at least 3.5kg, giving that population a once-daily capsule sprinkle option.